Izrael - angol - Ministry of Health

neopharm scientific ltd - cannabidiol drug substance ( cbd bds ); delta-9-tetrahydrocannabinol drug substance ( thc bds ) - oromucosal spray - cannabidiol drug substance ( cbd bds ) 25 mg / 1 ml; delta-9-tetrahydrocannabinol drug substance ( thc bds ) 27 mg / 1 ml - nabiximols - sativex is indicated, as add-on treatment, for symptom relief in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other medication and who demonstrate at least 20 % improvement in spasticity related symptoms during a four week trial of therapy.

Izrael - angol - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 10 mg - linagliptin and empagliflozin - jardiance 10mg is indicated: •to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.•as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus •to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Izrael - angol - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 25 mg - linagliptin and empagliflozin - jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Izrael - angol - Ministry of Health

a.m.i. medical technologies limited, israel - amorolfine as hydrochloride - lacquer - amorolfine as hydrochloride 5 %w/v - amorolfine - amorolfine - topical treatment of onycomycosis caused by dermatophytes, yeast and moulds.

Izrael - angol - Ministry of Health

teva israel ltd - fulvestrant - solution for injection - fulvestrant 50 mg/ml - fulvestrant - monotherapyfulvestrant teva is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy, or* with disease progression on endocrine therapy.combination therapyfulvestrant teva is indicated for the treatment of:- hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- hr- positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Izrael - angol - Ministry of Health

novartis israel ltd - ribociclib as succinate - film coated tablets - ribociclib as succinate 200 mg - ribociclib - kisqali is indicated in combination with:* a non-steroid aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer, as initial endocrine-based therapy.or* fulvestrant for the treatment of men and postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.

Izrael - angol - Ministry of Health

amgen europe b.v. - trastuzumab - powder for concentrate for solution for infusion - trastuzumab 150 mg/vial - trastuzumab - metastatic breast cancer (mbc)kanjinti is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress her2;1. as a single agent, for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease.2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.3. in combination with an aromatase inhibitor for the treatment of postmenopausal patient with hormone-receptor positive metastatic breast cancer.early breast cancer (ebc)kanjinti is indicated to treat patients with her2 positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines.kanjinti should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.kanjinti should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc 2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.

Izrael - angol - Ministry of Health

amgen europe b.v. - trastuzumab - powder for concentrate for solution for infusion - trastuzumab 420 mg/vial - trastuzumab - metastatic breast cancer (mbc)kanjinti is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress her2;1. as a single agent, for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease.2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.3. in combination with an aromatase inhibitor for the treatment of postmenopausal patient with hormone-receptor positive metastatic breast cancer.early breast cancer (ebc)kanjinti is indicated to treat patients with her2 positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines.kanjinti should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.kanjinti should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc 2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.

Izrael - angol - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin - film coated tablets - linagliptin 5 mg - linagliptin - linagliptin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. trajenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta.

Izrael - angol - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone - film coated tablets - dydrogesterone 10 mg - dydrogesterone - dydrogesterone - cases where progesterone supplement is needed.